The DYNC2H1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered for functional analysis of cytoplasmic dynein-2 heavy chain 1 (DYNC2H1) within a human hepatic adenocarcinoma context. This product provides a genetically heterogeneous pool of SK-HEP-1 cells harboring disruptions in the DYNC2H1 locus, generated via CRISPR/Cas9-mediated gene disruption. It is designed as a robust loss-of-function model for interrogating the molecular mechanisms of ciliary transport and signaling without prior clonal selection. The polyclonal format maintains cellular diversity and mitigates clonal artifacts, making it suitable for broad phenotypic screening and mechanistic studies in hepatocyte and endothelial-like cell environments.
SK-HEP-1 is a human liver adenocarcinoma cell line originally isolated from ascites, characterized by a unique endothelial-like phenotype and widely adopted as a surrogate model for hepatic sinusoidal endothelial cells and hepatocytes. These cells express markers typical of both hepatic and endothelial lineages, facilitating investigations into liver function, drug metabolism, and hepatocellular carcinoma progression. Their dual nature provides a physiologically relevant platform for studying ciliary biology at the interface of hepatic parenchyma and vasculature, especially where primary cilia are increasingly recognized as modulators of liver homeostasis and disease.
DYNC2H1 encodes the heavy chain component of cytoplasmic dynein-2, a microtubule-based motor protein integral to retrograde intraflagellar transport (IFT) within primary cilia. This motor forms a complex with subunits such as DYNC2LI1 and collaborates with the IFT-A complex (including IFT122 and IFT140) and IFT-B complex (including IFT88 and IFT57) to mediate cargo trafficking from the ciliary tip to the cell body. Loss of DYNC2H1 function stalls retrograde IFT, causing accumulation of IFT-B proteins in the cilium and disrupting ciliary maintenance. Consequently, ciliary-dependent signaling pathways, particularly Hedgehog signaling transduced via SMO and GLI transcription factors, are impaired. The gene is transcriptionally regulated by ciliogenic factors such as RFX and FOXJ1, positioning DYNC2H1 downstream of differentiation and cell cycle cues that govern ciliogenesis.
In the SK-HEP-1 model, DYNC2H1 knockout compromises primary cilium assembly and disables retrograde IFT, leading to defective Hedgehog pathway output and potential dysregulation of Wnt and TGF- signaling. Given the emerging role of hepatic primary cilia in sensing extracellular cues, bile flow, and metabolic signals, this knockout population offers a powerful tool to dissect ciliary contributions to liver pathobiology. The endothelial-like features of SK-HEP-1 further allow exploration of ciliary functions in sinusoidal endothelial cells, which are implicated in portal hypertension, fibrosis, and tumor?Cstroma interactions. Thus, the model bridges ciliopathy research and liver cancer biology, facilitating the study of ciliary dysfunction in adenocarcinoma initiation and progression.
This knockout cell population supports multiple research applications, including investigation of primary cilia structure and function in hepatic cells, dissection of ciliopathy mechanisms related to short-rib thoracic dysplasia and Jeune syndrome, and elucidation of Hedgehog-dependent processes in liver cancer. Typical assays include immunofluorescence staining for ciliary markers such as ARL13B and acetylated -tubulin, Western blotting for IFT components, Gli-luciferase reporter assays for Hedgehog activity, and RT-qPCR profiling of ciliogenesis-related transcripts. Additional analyses may employ scanning electron microscopy for ciliary ultrastructure or cell cycle studies to assess proliferative changes. Researchers interested in cilia-targeted drug screening or genetic modifier experiments will find this polyclonal knockout model an adaptable and physiologically relevant platform. For further details on validation and experimental support, contact Ascent Research.
